{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:51:25Z","timestamp":1794556285129,"version":"4.9.1"},"reference-count":217,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["23951"],"award-info":[{"award-number":["23951"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2013-02355449"],"award-info":[{"award-number":["GR-2013-02355449"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2013-02354892"],"award-info":[{"award-number":["RF-2013-02354892"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["GR 2017-0800"],"award-info":[{"award-number":["GR 2017-0800"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cachexia is a severe complication of cancer that adversely affects the course of the disease, with currently no effective treatments. It is characterized by a progressive atrophy of skeletal muscle and adipose tissue, resulting in weight loss, a reduced quality of life, and a shortened life expectancy. Although the cachectic condition primarily affects the skeletal muscle, a tissue that accounts for ~40% of total body weight, cachexia is considered a multi-organ disease that involves different tissues and organs, among which the cardiac muscle stands out for its relevance. Patients with cancer often experience severe cardiac abnormalities and manifest symptoms that are indicative of chronic heart failure, including fatigue, shortness of breath, and impaired exercise tolerance. Furthermore, cardiovascular complications are among the major causes of death in cancer patients who experienced cachexia. The lack of effective treatments for cancer cachexia underscores the need to improve our understanding of the underlying mechanisms. Increasing evidence links the wasting of the cardiac and skeletal muscles to metabolic alterations, primarily increased energy expenditure, and to increased proteolysis, ensuing from activation of the major proteolytic machineries of the cell, including ubiquitin-dependent proteolysis and autophagy. This review aims at providing an overview of the key mechanisms of cancer cachexia, with a major focus on those that are shared by the skeletal and cardiac muscles.<\/jats:p>","DOI":"10.1038\/s41389-020-00288-6","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T13:03:46Z","timestamp":1610111026000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia"],"prefix":"10.1038","volume":"10","author":[{"given":"Valentina","family":"Rausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8519-1552","authenticated-orcid":false,"given":"Paolo Ettore","family":"Porporato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-5296","authenticated-orcid":false,"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"288_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153\u2013166 (2012).","journal-title":"Cell Metab."},{"key":"288_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","volume":"15","author":"JM Argiles","year":"2018","unstructured":"Argiles, J. M., Stemmler, B., Lopez-Soriano, F. J. & Busquets, S. Inter-tissue communication in cancer cachexia. Nat. Rev. Endocrinol. 15, 9\u201320 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"288_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.3","volume":"5","author":"PE Porporato","year":"2016","unstructured":"Porporato, P. E. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis 5, e200 (2016).","journal-title":"Oncogenesis"},{"key":"288_CR4","doi-asserted-by":"publisher","unstructured":"Brancaccio, M., Pirozzi, F., Hirsch, E. & Ghigo, A. Mechanisms underlying the cross-talk between heart and cancer. J. Physiol. https:\/\/doi.org\/10.1113\/JP276746 (2019).","DOI":"10.1113\/JP276746"},{"key":"288_CR5","doi-asserted-by":"publisher","unstructured":"von Haehling, S. et al. Muscle wasting as an independent predictor of survival in patients with chronic heart failure. J. Cachexia Sarcopenia Muscle. https:\/\/doi.org\/10.1002\/jcsm.12603 (2020).","DOI":"10.1002\/jcsm.12603"},{"key":"288_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.yjmcc.2011.10.022","volume":"52","author":"A Schrepper","year":"2012","unstructured":"Schrepper, A., Schwarzer, M., Schope, M., Amorim, P. A. & Doenst, T. Biphasic response of skeletal muscle mitochondria to chronic cardiac pressure overload - role of respiratory chain complex activity. J. Mol. Cell Cardiol. 52, 125\u2013135 (2012).","journal-title":"J. Mol. Cell Cardiol."},{"key":"288_CR7","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1006\/jmcc.2001.1453","volume":"33","author":"L Dalla Libera","year":"2001","unstructured":"Dalla Libera, L. et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J. Mol. Cell Cardiol. 33, 1871\u20131878 (2001).","journal-title":"J. Mol. Cell Cardiol."},{"key":"288_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-020-00229-2","volume":"10","author":"T Nguyen","year":"2020","unstructured":"Nguyen, T. et al. Expression of MuRF1 or MuRF2 is essential for the induction of skeletal muscle atrophy and dysfunction in a murine pulmonary hypertension model. Skelet. Muscle 10, 12 (2020).","journal-title":"Skelet. Muscle"},{"key":"288_CR9","doi-asserted-by":"publisher","first-page":"9549036","DOI":"10.1155\/2016\/9549036","volume":"2016","author":"V Sala","year":"2016","unstructured":"Sala, V. et al. A new transgenic mouse model of heart failure and cardiac cachexia raised by sustained activation of met tyrosine kinase in the heart. Biomed. Res. Int. 2016, 9549036 (2016).","journal-title":"Biomed. Res. Int."},{"key":"288_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","volume":"34","author":"S Fulster","year":"2013","unstructured":"Fulster, S. et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur. Heart J. 34, 512\u2013519 (2013).","journal-title":"Eur. Heart J."},{"key":"288_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ehf2.12184","volume":"4","author":"A Barkhudaryan","year":"2017","unstructured":"Barkhudaryan, A., Scherbakov, N., Springer, J. & Doehner, W. Cardiac muscle wasting in individuals with cancer cachexia. ESC Heart Fail 4, 458\u2013467 (2017).","journal-title":"ESC Heart Fail"},{"key":"288_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fnut.2020.00004","volume":"7","author":"D Riccardi","year":"2020","unstructured":"Riccardi, D. et al. Plasma lipid profile and systemic inflammation in patients with cancer cachexia. Front Nutr. 7, 4 (2020).","journal-title":"Front Nutr."},{"key":"288_CR13","doi-asserted-by":"publisher","unstructured":"Sin, T. K. et al. Cancer takes a toll on skeletal muscle by releasing heat shock proteins-an emerging mechanism of cancer-induced cachexia. Cancers. https:\/\/doi.org\/10.3390\/cancers11091272 (2019).","DOI":"10.3390\/cancers11091272"},{"key":"288_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature07623","volume":"457","author":"S Kim","year":"2009","unstructured":"Kim, S. et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102\u2013106 (2009).","journal-title":"Nature"},{"key":"288_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature08780","volume":"464","author":"Q Zhang","year":"2010","unstructured":"Zhang, Q. et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104\u2013107 (2010).","journal-title":"Nature"},{"key":"288_CR16","doi-asserted-by":"publisher","first-page":"8260742","DOI":"10.1155\/2018\/8260742","volume":"2018","author":"E Manole","year":"2018","unstructured":"Manole, E., Ceafalan, L. C., Popescu, B. O., Dumitru, C. & Bastian, A. E. Myokines as possible therapeutic targets in cancer cachexia. J. Immunol. Res. 2018, 8260742 (2018).","journal-title":"J. Immunol. Res."},{"key":"288_CR17","first-page":"871","volume":"12","author":"YP Li","year":"1998","unstructured":"Li, Y. P., Schwartz, R. J., Waddell, I. D., Holloway, B. R. & Reid, M. B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J. 12, 871\u2013880 (1998).","journal-title":"FASEB J."},{"key":"288_CR18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1096\/fj.02-0759com","volume":"17","author":"YP Li","year":"2003","unstructured":"Li, Y. P. et al. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2\/E220k. FASEB J. 17, 1048\u20131057 (2003).","journal-title":"FASEB J."},{"key":"288_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/jcsm.12145","volume":"8","author":"H Ding","year":"2017","unstructured":"Ding, H. et al. Activin A induces skeletal muscle catabolism via p38beta mitogen-activated protein kinase. J. Cachexia Sarcopenia Muscle 8, 202\u2013212 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1096\/fj.04-2364com","volume":"19","author":"YP Li","year":"2005","unstructured":"Li, Y. P. et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1\/MAFbx in skeletal muscle. FASEB J. 19, 362\u2013370 (2005).","journal-title":"FASEB J."},{"key":"288_CR21","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto, A. et al. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 303, E410\u2013421 (2012).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"288_CR22","first-page":"6","volume":"61","author":"BA Konstantinov","year":"1989","unstructured":"Konstantinov, B. A., Tarichko, Iu,V., Cherepenion, L. P., Shabalkin, B. V. & Osipov, V. P. [Mortality in cardiac surgery]. Ter. Arkh. 61, 6\u201310 (1989).","journal-title":"Ter. Arkh."},{"key":"288_CR23","doi-asserted-by":"publisher","first-page":"2063179","DOI":"10.1155\/2018\/2063179","volume":"2018","author":"J Abrigo","year":"2018","unstructured":"Abrigo, J. et al. Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid. Med. Cell Longev. 2018, 2063179 (2018).","journal-title":"Oxid. Med. Cell Longev."},{"key":"288_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7670","volume":"6","author":"G Milan","year":"2015","unstructured":"Milan, G. et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. 6, 6670 (2015).","journal-title":"Nat. Commun."},{"key":"288_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fncel.2018.00126","volume":"12","author":"HA Bustamante","year":"2018","unstructured":"Bustamante, H. A. et al. Interplay between the autophagy-lysosomal pathway and the ubiquitin-proteasome system: A target for therapeutic development in Alzheimer\u2019s disease. Front. Cell Neurosci. 12, 126 (2018).","journal-title":"Front. Cell Neurosci."},{"key":"288_CR26","doi-asserted-by":"publisher","unstructured":"Yoshii, S. R. & Mizushima, N. Monitoring and measuring autophagy. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18091865 (2017).","DOI":"10.3390\/ijms18091865"},{"key":"288_CR27","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1007\/s00018-016-2255-5","volume":"73","author":"GL Grice","year":"2016","unstructured":"Grice, G. L. & Nathan, J. A. The recognition of ubiquitinated proteins by the proteasome. Cell Mol. Life Sci. 73, 3497\u20133506 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"288_CR28","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/0008-5472.CAN-10-3145","volume":"71","author":"PF Cosper","year":"2011","unstructured":"Cosper, P. F. & Leinwand, L. A. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 71, 1710\u20131720 (2011).","journal-title":"Cancer Res."},{"key":"288_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/jcsm.12116","volume":"7","author":"V Musolino","year":"2016","unstructured":"Musolino, V. et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J. Cachexia Sarcopenia Muscle 7, 555\u2013566 (2016).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4161\/auto.7.5.15102","volume":"7","author":"PK Paul","year":"2011","unstructured":"Paul, P. K. & Kumar, A. TRAF6 coordinates the activation of autophagy and ubiquitin-proteasome systems in atrophying skeletal muscle. Autophagy 7, 555\u2013556 (2011).","journal-title":"Autophagy"},{"key":"288_CR31","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1083\/jcb.201006098","volume":"191","author":"PK Paul","year":"2010","unstructured":"Paul, P. K. et al. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice. J. Cell Biol. 191, 1395\u20131411 (2010).","journal-title":"J. Cell Biol."},{"key":"288_CR32","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3892\/ijo.2013.1893","volume":"42","author":"ND Manne","year":"2013","unstructured":"Manne, N. D. et al. Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin\/+ mouse. Int. J. Oncol. 42, 2134\u20132140 (2013).","journal-title":"Int. J. Oncol."},{"key":"288_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/cvr\/cvr144","volume":"91","author":"TG Schips","year":"2011","unstructured":"Schips, T. G. et al. FoxO3 induces reversible cardiac atrophy and autophagy in a transgenic mouse model. Cardiovasc. Res. 91, 587\u2013597 (2011).","journal-title":"Cardiovasc. Res."},{"key":"288_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1161\/CIRCRESAHA.110.238717","volume":"109","author":"S Usui","year":"2011","unstructured":"Usui, S. et al. Endogenous muscle atrophy F-box mediates pressure overload-induced cardiac hypertrophy through regulation of nuclear factor-kappaB. Circ. Res. 109, 161\u2013171 (2011).","journal-title":"Circ. Res."},{"key":"288_CR35","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1172\/JCI66339","volume":"124","author":"T Zaglia","year":"2014","unstructured":"Zaglia, T. et al. Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy. J. Clin. Invest. 124, 2410\u20132424 (2014).","journal-title":"J. Clin. Invest."},{"key":"288_CR36","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/cvr\/cvs320","volume":"97","author":"T Zaglia","year":"2013","unstructured":"Zaglia, T. et al. Cardiac sympathetic neurons provide trophic signal to the heart via beta2-adrenoceptor-dependent regulation of proteolysis. Cardiovasc. Res. 97, 240\u2013250 (2013).","journal-title":"Cardiovasc. Res."},{"key":"288_CR37","first-page":"1321","volume":"39","author":"M Tian","year":"2011","unstructured":"Tian, M., Asp, M. L., Nishijima, Y. & Belury, M. A. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int. J. Oncol. 39, 1321\u20131326 (2011).","journal-title":"Int. J. Oncol."},{"key":"288_CR38","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Primers 4, 17105 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"288_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1096\/fj.13-240580","volume":"28","author":"MJ Puppa","year":"2014","unstructured":"Puppa, M. J., Gao, S., Narsale, A. A. & Carson, J. A. Skeletal muscle glycoprotein 130\u2019s role in Lewis lung carcinoma-induced cachexia. FASEB J. 28, 998\u20131009 (2014).","journal-title":"FASEB J."},{"key":"288_CR40","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/jcsm.12346","volume":"9","author":"SC Kandarian","year":"2018","unstructured":"Kandarian, S. C. et al. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J. Cachexia Sarcopenia Muscle 9, 1109\u20131120 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR41","doi-asserted-by":"publisher","first-page":"C706","DOI":"10.1152\/ajpcell.00626.2008","volume":"297","author":"W Li","year":"2009","unstructured":"Li, W., Moylan, J. S., Chambers, M. A., Smith, J. & Reid, M. B. Interleukin-1 stimulates catabolism in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 297, C706\u2013714 (2009).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"288_CR42","doi-asserted-by":"publisher","unstructured":"Callaway, C. S. et al. IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1\/2 axis to induce muscle atrophy. Cancers. https:\/\/doi.org\/10.3390\/cancers11121863 (2019).","DOI":"10.3390\/cancers11121863"},{"key":"288_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0769-2625(88)90148-1","volume":"139","author":"KJ Tracey","year":"1988","unstructured":"Tracey, K. J., Lowry, S. F. & Cerami, A. The pathophysiologic role of cachectin\/TNF in septic shock and cachexia. Ann. Inst. Pasteur Immunol. 139, 311\u2013317 (1988).","journal-title":"Ann. Inst. Pasteur Immunol."},{"key":"288_CR44","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1126\/science.289.5488.2363","volume":"289","author":"DC Guttridge","year":"2000","unstructured":"Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C. Y. & Baldwin, A. S. Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289, 2363\u20132366 (2000).","journal-title":"Science"},{"key":"288_CR45","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1172\/JCI68523","volume":"123","author":"WA He","year":"2013","unstructured":"He, W. A. et al. NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J. Clin. Invest. 123, 4821\u20134835 (2013).","journal-title":"J. Clin. Invest."},{"key":"288_CR46","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41591-018-0054-2","volume":"24","author":"G Wang","year":"2018","unstructured":"Wang, G. et al. Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770\u2013781 (2018).","journal-title":"Nat. Med."},{"key":"288_CR47","doi-asserted-by":"publisher","unstructured":"Shakri, A. R. et al. Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers. https:\/\/doi.org\/10.3390\/cancers12010003 (2019).","DOI":"10.3390\/cancers12010003"},{"key":"288_CR48","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/jcsm.12225","volume":"8","author":"KA Michaelis","year":"2017","unstructured":"Michaelis, K. A. et al. Establishment and characterization of a novel murine model of pancreatic cancer cachexia. J. Cachexia Sarcopenia Muscle 8, 824\u2013838 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/jn\/nxx041","volume":"148","author":"TB Aydemir","year":"2018","unstructured":"Aydemir, T. B. & Cousins, R. J. The multiple faces of the metal transporter ZIP14 (SLC39A14). J. Nutr. 148, 174\u2013184 (2018).","journal-title":"J. Nutr."},{"key":"288_CR50","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/jcmm.13480","volume":"22","author":"Y Olgar","year":"2018","unstructured":"Olgar, Y. et al. Increased free Zn(2+) correlates induction of sarco(endo)plasmic reticulum stress via altered expression levels of Zn(2+) -transporters in heart failure. J. Cell. Mol. Med. 22, 1944\u20131956 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"288_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132786","volume":"10","author":"SH Greco","year":"2015","unstructured":"Greco, S. H. et al. TGF-beta blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS ONE 10, e0132786 (2015).","journal-title":"PLoS ONE"},{"key":"288_CR52","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nrc3500","volume":"13","author":"LM Wakefield","year":"2013","unstructured":"Wakefield, L. M. & Hill, C. S. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13, 328\u2013341 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"288_CR53","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","volume":"21","author":"DL Waning","year":"2015","unstructured":"Waning, D. L. et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21, 1262\u20131271 (2015).","journal-title":"Nat. Med."},{"key":"288_CR54","doi-asserted-by":"publisher","first-page":"49831","DOI":"10.1074\/jbc.M204291200","volume":"277","author":"B Langley","year":"2002","unstructured":"Langley, B. et al. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J. Biol. Chem. 277, 49831\u201349840 (2002).","journal-title":"J. Biol. Chem."},{"key":"288_CR55","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1083\/jcb.200207056","volume":"162","author":"S McCroskery","year":"2003","unstructured":"McCroskery, S., Thomas, M., Maxwell, L., Sharma, M. & Kambadur, R. Myostatin negatively regulates satellite cell activation and self-renewal. J. Cell Biol. 162, 1135\u20131147 (2003).","journal-title":"J. Cell Biol."},{"key":"288_CR56","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1126\/science.1069525","volume":"296","author":"TA Zimmers","year":"2002","unstructured":"Zimmers, T. A. et al. Induction of cachexia in mice by systemically administered myostatin. Science 296, 1486\u20131488 (2002).","journal-title":"Science"},{"key":"288_CR57","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2362.2008.01970.x","volume":"38","author":"P Costelli","year":"2008","unstructured":"Costelli, P. et al. Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Invest. 38, 531\u2013538 (2008).","journal-title":"Eur. J. Clin. Invest."},{"key":"288_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijcard.2017.03.153","volume":"238","author":"J Ishida","year":"2017","unstructured":"Ishida, J. et al. Myostatin signaling is up-regulated in female patients with advanced heart failure. Int. J. Cardiol. 238, 37\u201342 (2017).","journal-title":"Int. J. Cardiol."},{"key":"288_CR59","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.109.882068","volume":"121","author":"J Heineke","year":"2010","unstructured":"Heineke, J. et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121, 419\u2013425 (2010).","journal-title":"Circulation"},{"key":"288_CR60","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12209","volume":"8","author":"A Loumaye","year":"2017","unstructured":"Loumaye, A. et al. Circulating Activin A predicts survival in cancer patients. J. Cachexia Sarcopenia Muscle 8, 768\u2013777 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531\u2013543 (2010).","journal-title":"Cell"},{"key":"288_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-016-0098-2","volume":"6","author":"S Hatakeyama","year":"2016","unstructured":"Hatakeyama, S. et al. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet. Muscle 6, 26 (2016).","journal-title":"Skelet. Muscle"},{"key":"288_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1152\/japplphysiol.00210.2014","volume":"117","author":"AN Kavazis","year":"2014","unstructured":"Kavazis, A. N., Smuder, A. J. & Powers, S. K. Effects of short-term endurance exercise training on acute doxorubicin-induced FoxO transcription in cardiac and skeletal muscle. J. Appl Physiol. 117, 223\u2013230 (2014).","journal-title":"J. Appl Physiol."},{"key":"288_CR64","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jcsm.12265","volume":"9","author":"JJ Hulmi","year":"2018","unstructured":"Hulmi, J. J. et al. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. J. Cachexia Sarcopenia Muscle 9, 417\u2013432 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1517\/13543784.2013.738666","volume":"22","author":"SZ Fields","year":"2013","unstructured":"Fields, S. Z. et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin. Investig. Drugs 22, 87\u2013101 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"288_CR66","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","volume":"25","author":"JJ Tao","year":"2019","unstructured":"Tao, J. J. et al. First-in-human phase I study of the activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. Clin. Cancer Res. 25, 5458\u20135465 (2019).","journal-title":"Clin. Cancer Res."},{"key":"288_CR67","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcsm.12205","volume":"8","author":"DS Rooks","year":"2017","unstructured":"Rooks, D. S. et al. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J. Cachexia Sarcopenia Muscle 8, 727\u2013734 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","volume":"199","author":"MI Polkey","year":"2019","unstructured":"Polkey, M. I. et al. Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial. Am. J. Respir. Crit. Care Med. 199, 313\u2013320 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"288_CR69","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/10409238.2019.1610722","volume":"54","author":"MA Egerman","year":"2019","unstructured":"Egerman, M. A. & Glass, D. J. The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis. Crit. Rev. Biochem. Mol. Biol. 54, 174\u2013183 (2019).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"288_CR70","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00395-017-0639-9","volume":"112","author":"TA Zimmers","year":"2017","unstructured":"Zimmers, T. A. et al. Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting. Basic Res. Cardiol. 112, 48 (2017).","journal-title":"Basic Res. Cardiol."},{"key":"288_CR71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.15252\/emmm.201607231","volume":"9","author":"DW Hammers","year":"2017","unstructured":"Hammers, D. W. et al. Supraphysiological levels of GDF11 induce striated muscle atrophy. EMBO Mol. Med. 9, 531\u2013544 (2017).","journal-title":"EMBO Mol. Med."},{"key":"288_CR72","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1161\/CIRCRESAHA.118.312955","volume":"123","author":"SC Harper","year":"2018","unstructured":"Harper, S. C. et al. GDF11 decreases pressure overload-induced hypertrophy, but can cause severe cachexia and premature death. Circ. Res. 123, 1220\u20131231 (2018).","journal-title":"Circ. Res."},{"key":"288_CR73","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.celrep.2018.01.044","volume":"22","author":"JE Jones","year":"2018","unstructured":"Jones, J. E. et al. Supraphysiologic administration of GDF11 induces cachexia in part by upregulating GDF15. Cell Rep. 22, 1522\u20131530 (2018).","journal-title":"Cell Rep."},{"key":"288_CR74","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jcsm.12077","volume":"7","author":"L Lerner","year":"2016","unstructured":"Lerner, L. et al. MAP3K11\/GDF15 axis is a critical driver of cancer cachexia. J. Cachexia Sarcopenia Muscle 7, 467\u2013482 (2016).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR75","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948804","volume":"21","author":"M Ost","year":"2020","unstructured":"Ost, M. et al. Muscle-derived GDF15 drives diurnal anorexia and systemic metabolic remodeling during mitochondrial stress. EMBO Rep. 21, e48804 (2020).","journal-title":"EMBO Rep."},{"key":"288_CR76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.freeradbiomed.2016.02.018","volume":"98","author":"M Ost","year":"2016","unstructured":"Ost, M., Coleman, V., Kasch, J. & Klaus, S. Regulation of myokine expression: role of exercise and cellular stress. Free Radic. Biol. Med. 98, 78\u201389 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"288_CR77","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1161\/CIRCRESAHA.114.302653","volume":"114","author":"PP Rainer","year":"2014","unstructured":"Rainer, P. P. et al. Cardiomyocyte-specific transforming growth factor beta suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction. Circ. Res. 114, 1246\u20131257 (2014).","journal-title":"Circ. Res."},{"key":"288_CR78","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson, P. J. et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med. 23, 1215\u20131219 (2017).","journal-title":"Nat. Med."},{"key":"288_CR79","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158\u20131166 (2017).","journal-title":"Nat. Med."},{"key":"288_CR80","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150\u20131157 (2017).","journal-title":"Nat. Med."},{"key":"288_CR81","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm1677","volume":"13","author":"H Johnen","year":"2007","unstructured":"Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13, 1333\u20131340 (2007).","journal-title":"Nat. Med."},{"key":"288_CR82","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jcsm.12033","volume":"6","author":"L Lerner","year":"2015","unstructured":"Lerner, L. et al. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients. J. Cachexia Sarcopenia Muscle 6, 317\u2013324 (2015).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR83","doi-asserted-by":"publisher","unstructured":"Villars, F. O., Pietra, C., Giuliano, C., Lutz, T. A. & Riediger, T. Oral treatment with the ghrelin receptor agonist HM01 attenuates cachexia in mice bearing colon-26 (C26) tumors. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms18050986 (2017).","DOI":"10.3390\/ijms18050986"},{"key":"288_CR84","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/jcsm.12169","volume":"8","author":"T Borner","year":"2017","unstructured":"Borner, T. et al. Anorexia-cachexia syndrome in hepatoma tumour-bearing rats requires the area postrema but not vagal afferents and is paralleled by increased MIC-1\/GDF15. J. Cachexia Sarcopenia Muscle 8, 417\u2013427 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR85","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2019.12.004","volume":"31","author":"T Borner","year":"2020","unstructured":"Borner, T. et al. GDF15 induces anorexia through nausea and emesis. Cell Metab. 31, 351\u2013362. e355 (2020).","journal-title":"Cell Metab."},{"key":"288_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.52","volume":"8","author":"E Silk","year":"2017","unstructured":"Silk, E., Zhao, H., Weng, H. & Ma, D. The role of extracellular histone in organ injury. Cell Death Dis. 8, e2812 (2017).","journal-title":"Cell Death Dis."},{"key":"288_CR87","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","volume":"138","author":"M Li","year":"2018","unstructured":"Li, M. et al. Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 138, 696\u2013711 (2018).","journal-title":"Circulation"},{"key":"288_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00726-x","volume":"8","author":"G Zhang","year":"2017","unstructured":"Zhang, G. et al. Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017).","journal-title":"Nat. Commun."},{"key":"288_CR89","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044\u20131066 (2020).","journal-title":"Cell"},{"key":"288_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/intimm\/dxh186","volume":"17","author":"K Takeda","year":"2005","unstructured":"Takeda, K. & Akira, S. Toll-like receptors in innate immunity. Int. Immunol. 17, 1\u201314 (2005).","journal-title":"Int. Immunol."},{"key":"288_CR91","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1165\/rcmb.2011-0119OC","volume":"47","author":"RC Langen","year":"2012","unstructured":"Langen, R. C. et al. NF-kappaB activation is required for the transition of pulmonary inflammation to muscle atrophy. Am. J. Respir. Cell Mol. Biol. 47, 288\u2013297 (2012).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"288_CR92","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai, D. et al. IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice. Cell 119, 285\u2013298 (2004).","journal-title":"Cell"},{"key":"288_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02347-2","volume":"7","author":"G Zhang","year":"2017","unstructured":"Zhang, G. et al. Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. Sci. Rep. 7, 2273 (2017).","journal-title":"Sci. Rep."},{"key":"288_CR94","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/archotol.133.12.1263","volume":"133","author":"TY Cannon","year":"2007","unstructured":"Cannon, T. Y. et al. The effect of altered Toll-like receptor 4 signaling on cancer cachexia. Arch. Otolaryngol. Head Neck Surg. 133, 1263\u20131269 (2007).","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"288_CR95","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jcsm.12138","volume":"8","author":"N Johns","year":"2017","unstructured":"Johns, N. et al. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. J. Cachexia Sarcopenia Muscle 8, 122\u2013130 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR96","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1073\/pnas.1402714111","volume":"111","author":"WA He","year":"2014","unstructured":"He, W. A. et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl Acad. Sci. USA 111, 4525\u20134529 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"288_CR97","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1158\/0008-5472.CAN-17-3878","volume":"78","author":"F Calore","year":"2018","unstructured":"Calore, F. et al. The TLR7\/8\/9 antagonist IMO-8503 inhibits cancer-induced cachexia. Cancer Res. 78, 6680\u20136690 (2018).","journal-title":"Cancer Res."},{"key":"288_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12657-w","volume":"10","author":"KA Michaelis","year":"2019","unstructured":"Michaelis, K. A. et al. The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nat. Commun. 10, 4682 (2019).","journal-title":"Nat. Commun."},{"key":"288_CR99","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.cardiores.2006.09.011","volume":"72","author":"JH Boyd","year":"2006","unstructured":"Boyd, J. H., Mathur, S., Wang, Y., Bateman, R. M. & Walley, K. R. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc. Res. 72, 384\u2013393 (2006).","journal-title":"Cardiovasc. Res."},{"key":"288_CR100","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.yjmcc.2006.07.006","volume":"41","author":"G Hall","year":"2006","unstructured":"Hall, G., Hasday, J. D. & Rogers, T. B. Regulating the regulator: NF-kappaB signaling in heart. J. Mol. Cell Cardiol. 41, 580\u2013591 (2006).","journal-title":"J. Mol. Cell Cardiol."},{"key":"288_CR101","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10557-020-06946-6","volume":"34","author":"M Shah","year":"2020","unstructured":"Shah, M., Yellon, D. M. & Davidson, S. M. The role of extracellular DNA and histones in ischaemia-reperfusion injury of the myocardium. Cardiovasc. Drugs Ther. 34, 123\u2013131 (2020).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"288_CR102","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo, S. & Abbate, A. The NLRP3 inflammasome in acute myocardial infarction. Nat. Rev. Cardiol. 15, 203\u2013214 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"288_CR103","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/ismej.2015.209","volume":"10","author":"LB Bindels","year":"2016","unstructured":"Bindels, L. B. et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J. 10, 1456\u20131470 (2016).","journal-title":"ISME J."},{"key":"288_CR104","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fcimb.2019.00305","volume":"9","author":"L Genton","year":"2019","unstructured":"Genton, L. et al. Targeting the gut microbiota to treat cachexia. Front. Cell Infect. Microbiol. 9, 305 (2019).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"288_CR105","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.trecan.2016.07.005","volume":"2","author":"S Kir","year":"2016","unstructured":"Kir, S. & Spiegelman, B. M. Cachexia & brown fat: a burning issue in cancer. Trends Cancer 2, 461\u2013463 (2016).","journal-title":"Trends Cancer"},{"key":"288_CR106","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513, 100\u2013104 (2014).","journal-title":"Nature"},{"key":"288_CR107","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0065-230X(08)60496-0","volume":"2","author":"LD Fenninger","year":"1954","unstructured":"Fenninger, L. D. & Mider, G. B. Energy and nitrogen metabolism in cancer. Adv. Cancer Res. 2, 229\u2013253 (1954).","journal-title":"Adv. Cancer Res."},{"key":"288_CR108","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1158\/0008-5472.CAN-13-1052","volume":"74","author":"Y Luo","year":"2014","unstructured":"Luo, Y. et al. Cancer usurps skeletal muscle as an energy repository. Cancer Res. 74, 330\u2013340 (2014).","journal-title":"Cancer Res."},{"key":"288_CR109","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbadis.2014.02.003","volume":"1842","author":"CM Julienne","year":"2014","unstructured":"Julienne, C. M. et al. Cardiolipin content is involved in liver mitochondrial energy wasting associated with cancer-induced cachexia without the involvement of adenine nucleotide translocase. Biochim. Biophys. Acta 1842, 726\u2013733 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"288_CR110","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","volume":"20","author":"M Petruzzelli","year":"2014","unstructured":"Petruzzelli, M. et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433\u2013447 (2014).","journal-title":"Cell Metab."},{"key":"288_CR111","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","volume":"23","author":"S Kir","year":"2016","unstructured":"Kir, S. et al. PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. 23, 315\u2013323 (2016).","journal-title":"Cell Metab."},{"key":"288_CR112","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/jcsm.12403","volume":"10","author":"Y Okugawa","year":"2019","unstructured":"Okugawa, Y. et al. Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients. J. Cachexia Sarcopenia Muscle 10, 536\u2013548 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR113","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM198809013190906","volume":"319","author":"AE Broadus","year":"1988","unstructured":"Broadus, A. E. et al. Identification of a novel parathyroid hormone-like peptide. N. Engl. J. Med. 319, 556\u2013563 (1988).","journal-title":"N. Engl. J. Med."},{"key":"288_CR114","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.1073\/pnas.1601650113","volume":"113","author":"A Karlstaedt","year":"2016","unstructured":"Karlstaedt, A. et al. Oncometabolite d-2-hydroxyglutarate impairs alpha-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc. Natl Acad. Sci. USA 113, 10436\u201310441 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"288_CR115","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.echo.2017.07.016","volume":"30","author":"B Assuncao","year":"2017","unstructured":"Assuncao, B. et al. Acute leukemia is associated with cardiac alterations before chemotherapy. J. Am. Soc. Echocardiogr. 30, 1111\u20131118 (2017).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"288_CR116","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaccao.2019.10.008","volume":"1","author":"Y Kang","year":"2019","unstructured":"Kang, Y. et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC CardioOncol 1, 208\u2013217 (2019).","journal-title":"JACC CardioOncol"},{"key":"288_CR117","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/bloodadvances.2019000955","volume":"4","author":"NR Neuendorff","year":"2020","unstructured":"Neuendorff, N. R. et al. Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper. Blood Adv. 4, 762\u2013775 (2020).","journal-title":"Blood Adv."},{"key":"288_CR118","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/0973-029X.86670","volume":"15","author":"R Dhanapal","year":"2011","unstructured":"Dhanapal, R., Saraswathi, T. & Govind, R. N. Cancer cachexia. J. Oral. Maxillofac. Pathol. 15, 257\u2013260 (2011).","journal-title":"J. Oral. Maxillofac. Pathol."},{"key":"288_CR119","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2016.04.039","volume":"165","author":"S Masri","year":"2016","unstructured":"Masri, S. et al. Lung adenocarcinoma distally rewires hepatic circadian homeostasis. Cell 165, 896\u2013909 (2016).","journal-title":"Cell"},{"key":"288_CR120","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1172\/JCI10762","volume":"106","author":"HN Ginsberg","year":"2000","unstructured":"Ginsberg, H. N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453\u2013458 (2000).","journal-title":"J. Clin. Invest."},{"key":"288_CR121","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/521430a","volume":"521","author":"EF Wagner","year":"2015","unstructured":"Wagner, E. F. & Petruzzelli, M. Cancer metabolism: a waste of insulin interference. Nature 521, 430\u2013431 (2015).","journal-title":"Nature"},{"key":"288_CR122","first-page":"647","volume":"14","author":"AM Rofe","year":"1994","unstructured":"Rofe, A. M., Bourgeois, C. S., Coyle, P., Taylor, A. & Abdi, E. A. Altered insulin response to glucose in weight-losing cancer patients. Anticancer Res. 14, 647\u2013650 (1994).","journal-title":"Anticancer Res."},{"key":"288_CR123","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ccell.2018.08.016","volume":"34","author":"H Ye","year":"2018","unstructured":"Ye, H. et al. Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells. Cancer Cell 34, 659\u201373 e656 (2018).","journal-title":"Cancer Cell"},{"key":"288_CR124","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1101\/gad.276733.115","volume":"30","author":"M Petruzzelli","year":"2016","unstructured":"Petruzzelli, M. & Wagner, E. F. Mechanisms of metabolic dysfunction in cancer-associated cachexia. Genes Dev. 30, 489\u2013501 (2016).","journal-title":"Genes Dev."},{"key":"288_CR125","doi-asserted-by":"publisher","first-page":"R674","DOI":"10.1152\/ajpregu.00104.2006","volume":"291","author":"P Costelli","year":"2006","unstructured":"Costelli, P. et al. IGF-1 is downregulated in experimental cancer cachexia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R674\u2013683 (2006).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"288_CR126","doi-asserted-by":"publisher","unstructured":"Thackeray, J. T. et al. Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.93098 (2017).","DOI":"10.1172\/jci.insight.93098"},{"key":"288_CR127","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nm.4093","volume":"22","author":"T Fukawa","year":"2016","unstructured":"Fukawa, T. et al. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat. Med. 22, 666\u2013671 (2016).","journal-title":"Nat. Med."},{"key":"288_CR128","doi-asserted-by":"publisher","first-page":"6419805","DOI":"10.1155\/2018\/6419805","volume":"2018","author":"E Wyart","year":"2018","unstructured":"Wyart, E. et al. Metabolic alterations in a slow-paced model of pancreatic cancer-induced wasting. Oxid. Med. Cell Longev. 2018, 6419805 (2018).","journal-title":"Oxid. Med. Cell Longev."},{"key":"288_CR129","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/jcsm.12226","volume":"8","author":"F Molinari","year":"2017","unstructured":"Molinari, F. et al. The mitochondrial metabolic reprogramming agent trimetazidine as an \u2018exercise mimetic\u2019 in cachectic C26-bearing mice. J. Cachexia Sarcopenia Muscle 8, 954\u2013973 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR130","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1126\/science.1198973","volume":"333","author":"SK Das","year":"2011","unstructured":"Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 333, 233\u2013238 (2011).","journal-title":"Science"},{"key":"288_CR131","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cmet.2007.10.013","volume":"7","author":"TR Koves","year":"2008","unstructured":"Koves, T. R. et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45\u201356 (2008).","journal-title":"Cell Metab."},{"key":"288_CR132","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2012.04.010","volume":"15","author":"DM Muoio","year":"2012","unstructured":"Muoio, D. M. & Neufer, P. D. Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab. 15, 595\u2013605 (2012).","journal-title":"Cell Metab."},{"key":"288_CR133","doi-asserted-by":"publisher","first-page":"7153610","DOI":"10.1155\/2018\/7153610","volume":"2018","author":"F Penna","year":"2018","unstructured":"Penna, F., Ballaro, R., Beltra, M., De Lucia, S. & Costelli, P. Modulating metabolism to improve cancer-induced muscle wasting. Oxid. Med. Cell Longev. 2018, 7153610 (2018).","journal-title":"Oxid. Med. Cell Longev."},{"key":"288_CR134","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41586-020-1992-7","volume":"578","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. TLR9 and beclin 1 crosstalk regulates muscle AMPK activation in exercise. Nature 578, 605\u2013609 (2020).","journal-title":"Nature"},{"key":"288_CR135","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3324\/haematol.2019.232124","volume":"105","author":"C Camaschella","year":"2020","unstructured":"Camaschella, C., Nai, A. & Silvestri, L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica 105, 260\u2013272 (2020).","journal-title":"Haematologica"},{"key":"288_CR136","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00392-018-1344-x","volume":"108","author":"T Bekfani","year":"2019","unstructured":"Bekfani, T. et al. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. Clin. Res. Cardiol. 108, 203\u2013211 (2019).","journal-title":"Clin. Res. Cardiol."},{"key":"288_CR137","doi-asserted-by":"publisher","first-page":"e125618","DOI":"10.1172\/jci.insight.125618","volume":"4","author":"YJ Chung","year":"2019","unstructured":"Chung, Y. J. et al. Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity. JCI Insight 4, e125618 (2019).","journal-title":"JCI Insight"},{"key":"288_CR138","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","volume":"7","author":"S von Haehling","year":"2019","unstructured":"von Haehling, S., Ebner, N., Evertz, R., Ponikowski, P. & Anker, S. D. Iron deficiency in heart failure: an overview. JACC Heart Fail 7, 36\u201346 (2019).","journal-title":"JACC Heart Fail"},{"key":"288_CR139","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/nyas.13008","volume":"1368","author":"DH Manz","year":"2016","unstructured":"Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M. & Torti, S. V. Iron and cancer: recent insights. Ann. N. Y. Acad. Sci. 1368, 149\u2013161 (2016).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"288_CR140","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ejhf.1434","volume":"21","author":"K Ghafourian","year":"2019","unstructured":"Ghafourian, K., Chang, H. C. & Ardehali, H. Intravenous iron therapy in heart failure: a different perspective. Eur. J. Heart Fail 21, 703\u2013714 (2019).","journal-title":"Eur. J. Heart Fail"},{"key":"288_CR141","doi-asserted-by":"publisher","first-page":"247","DOI":"10.15252\/emmm.201505748","volume":"8","author":"HC Chang","year":"2016","unstructured":"Chang, H. C. et al. Reduction in mitochondrial iron alleviates cardiac damage during injury. EMBO Mol. Med. 8, 247\u2013267 (2016).","journal-title":"EMBO Mol. Med."},{"key":"288_CR142","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cardfail.2015.09.017","volume":"21","author":"Y Nagatomo","year":"2015","unstructured":"Nagatomo, Y. & Tang, W. H. Intersections between microbiome and heart failure: revisiting the gut hypothesis. J. Card. Fail. 21, 973\u2013980 (2015).","journal-title":"J. Card. Fail."},{"key":"288_CR143","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cell.2020.02.016","volume":"180","author":"I Nemet","year":"2020","unstructured":"Nemet, I. et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell 180, 862\u2013877.e822 (2020).","journal-title":"Cell"},{"key":"288_CR144","doi-asserted-by":"publisher","first-page":"6458094","DOI":"10.1155\/2018\/6458094","volume":"2018","author":"J Bu","year":"2018","unstructured":"Bu, J. & Wang, Z. Cross-talk between gut microbiota and heart via the routes of metabolite and immunity. Gastroenterol. Res. Pract. 2018, 6458094 (2018).","journal-title":"Gastroenterol. Res. Pract."},{"key":"288_CR145","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/eji.201646879","volume":"48","author":"S Ascher","year":"2018","unstructured":"Ascher, S. & Reinhardt, C. The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. Eur. J. Immunol. 48, 564\u2013575 (2018).","journal-title":"Eur. J. Immunol."},{"key":"288_CR146","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5306\/wjco.v7.i2.200","volume":"7","author":"M Pevsner-Fischer","year":"2016","unstructured":"Pevsner-Fischer, M. et al. Role of the microbiome in non-gastrointestinal cancers. World J. Clin. Oncol. 7, 200\u2013213 (2016).","journal-title":"World J. Clin. Oncol."},{"key":"288_CR147","first-page":"483","volume":"66","author":"PC Konturek","year":"2015","unstructured":"Konturek, P. C. et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J. Physiol. Pharmacol. 66, 483\u2013491 (2015).","journal-title":"J. Physiol. Pharmacol."},{"key":"288_CR148","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.clnu.2014.10.003","volume":"34","author":"L Genton","year":"2015","unstructured":"Genton, L., Cani, P. D. & Schrenzel, J. Alterations of gut barrier and gut microbiota in food restriction, food deprivation and protein-energy wasting. Clin. Nutr. 34, 341\u2013349 (2015).","journal-title":"Clin. Nutr."},{"key":"288_CR149","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1189\/jlb.1209775","volume":"87","author":"C Erridge","year":"2010","unstructured":"Erridge, C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J. Leukoc. Biol. 87, 989\u2013999 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"288_CR150","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.surg.2012.02.021","volume":"152","author":"K Tanaka","year":"2012","unstructured":"Tanaka, K. et al. Impact of perioperative administration of synbiotics in patients with esophageal cancer undergoing esophagectomy: a prospective randomized controlled trial. Surgery 152, 832\u2013842 (2012).","journal-title":"Surgery"},{"key":"288_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131009","volume":"10","author":"LB Bindels","year":"2015","unstructured":"Bindels, L. B. et al. Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia in mice. PLoS ONE 10, e0131009 (2015).","journal-title":"PLoS ONE"},{"key":"288_CR152","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/ejhf.1439","volume":"21","author":"M Russo","year":"2019","unstructured":"Russo, M. et al. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity. Eur. J. Heart Fail. 21, 519\u2013528 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"288_CR153","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/SPC.0000000000000382","volume":"12","author":"F Pin","year":"2018","unstructured":"Pin, F., Couch, M. E. & Bonetto, A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr. Opin. Support Palliat. Care 12, 420\u2013426 (2018).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"288_CR154","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jcsm.12360","volume":"10","author":"F Pin","year":"2019","unstructured":"Pin, F., Barreto, R., Couch, M. E., Bonetto, A. & O\u2019Connell, T. M. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia Sarcopenia Muscle 10, 140\u2013154 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR155","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.critrevonc.2018.03.014","volume":"126","author":"HM Babiker","year":"2018","unstructured":"Babiker, H. M. et al. Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit. Rev. Oncol. Hematol. 126, 186\u2013200 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"288_CR156","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115372","volume":"10","author":"R Altena","year":"2015","unstructured":"Altena, R. et al. Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage. PLoS ONE 10, e0115372 (2015).","journal-title":"PLoS ONE"},{"key":"288_CR157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183662","volume":"12","author":"DW Edwardson","year":"2017","unstructured":"Edwardson, D. W. et al. Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS ONE 12, e0183662 (2017).","journal-title":"PLoS ONE"},{"key":"288_CR158","first-page":"231","volume":"110","author":"HW Pogrebniak","year":"1991","unstructured":"Pogrebniak, H. W., Matthews, W. & Pass, H. I. Chemotherapy amplifies production of tumor necrosis factor. Surgery 110, 231\u2013237 (1991).","journal-title":"Surgery"},{"key":"288_CR159","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1017\/S0029665118000186","volume":"77","author":"DL Schiessel","year":"2018","unstructured":"Schiessel, D. L. & Baracos, V. E. Barriers to cancer nutrition therapy: excess catabolism of muscle and adipose tissues induced by tumour products and chemotherapy. Proc. Nutr. Soc. 77, 394\u2013402 (2018).","journal-title":"Proc. Nutr. Soc."},{"key":"288_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13504-y","volume":"7","author":"G Sirago","year":"2017","unstructured":"Sirago, G. et al. Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia. Sci. Rep. 7, 13017 (2017).","journal-title":"Sci. Rep."},{"key":"288_CR161","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fphar.2017.00137","volume":"8","author":"JC Sorensen","year":"2017","unstructured":"Sorensen, J. C. et al. BGP-15 protects against oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Front. Pharmacol. 8, 137 (2017).","journal-title":"Front. Pharmacol."},{"key":"288_CR162","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.taap.2010.11.003","volume":"250","author":"A Fanzani","year":"2011","unstructured":"Fanzani, A., Zanola, A., Rovetta, F., Rossi, S. & Aleo, M. F. Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol. Appl. Pharmacol. 250, 312\u2013321 (2011).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"288_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106489","volume":"9","author":"TP Braun","year":"2014","unstructured":"Braun, T. P. et al. Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS ONE 9, e106489 (2014).","journal-title":"PLoS ONE"},{"key":"288_CR164","doi-asserted-by":"publisher","first-page":"R227","DOI":"10.1152\/ajpregu.00299.2019","volume":"318","author":"RN Montalvo","year":"2020","unstructured":"Montalvo, R. N., Doerr, V., Min, K., Szeto, H. H. & Smuder, A. J. Doxorubicin-induced oxidative stress differentially regulates proteolytic signaling in cardiac and skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 318, R227\u2013R233 (2020).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"288_CR165","doi-asserted-by":"publisher","first-page":"118493","DOI":"10.1016\/j.bbamcr.2019.06.007","volume":"1867","author":"M Li","year":"2020","unstructured":"Li, M., Russo, M., Pirozzi, F., Tocchetti, C. G. & Ghigo, A. Autophagy and cancer therapy cardiotoxicity: from molecular mechanisms to therapeutic opportunities. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118493 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"288_CR166","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","volume":"133","author":"DL Li","year":"2016","unstructured":"Li, D. L. et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation 133, 1668\u20131687 (2016).","journal-title":"Circulation"},{"key":"288_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37862-3","volume":"9","author":"CS Abdullah","year":"2019","unstructured":"Abdullah, C. S. et al. Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci. Rep. 9, 2002 (2019).","journal-title":"Sci. Rep."},{"key":"288_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/apha.13400","volume":"229","author":"AE Hiensch","year":"2020","unstructured":"Hiensch, A. E. et al. Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways. Acta Physiol. 229, 1\u201318 (2020).","journal-title":"Acta Physiol."},{"key":"288_CR169","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1089\/ars.2011.3965","volume":"15","author":"LA Gilliam","year":"2011","unstructured":"Gilliam, L. A. & St Clair, D. K. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid. Redox Signal. 15, 2543\u20132563 (2011).","journal-title":"Antioxid. Redox Signal."},{"key":"288_CR170","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.freeradbiomed.2013.08.191","volume":"65","author":"LAA Gilliam","year":"2013","unstructured":"Gilliam, L. A. A. et al. The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic. Biol. Med. 65, 988\u2013996 (2013).","journal-title":"Free Radic. Biol. Med."},{"key":"288_CR171","doi-asserted-by":"publisher","first-page":"C195","DOI":"10.1152\/ajpcell.00217.2011","volume":"302","author":"LA Gilliam","year":"2012","unstructured":"Gilliam, L. A. et al. Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 302, C195\u2013202 (2012).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"288_CR172","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1152\/japplphysiol.00677.2010","volume":"110","author":"AJ Smuder","year":"2011","unstructured":"Smuder, A. J., Kavazis, A. N., Min, K. & Powers, S. K. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J. Appl. Physiol. 110, 935\u2013942 (2011).","journal-title":"J. Appl. Physiol."},{"key":"288_CR173","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.freeradbiomed.2010.06.025","volume":"49","author":"AJ Smuder","year":"2010","unstructured":"Smuder, A. J., Kavazis, A. N., Hudson, M. B., Nelson, W. B. & Powers, S. K. Oxidation enhances myofibrillar protein degradation via calpain and caspase-3. Free Radic. Biol. Med. 49, 1152\u20131160 (2010).","journal-title":"Free Radic. Biol. Med."},{"key":"288_CR174","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1113\/jphysiol.2014.286518","volume":"593","author":"K Min","year":"2015","unstructured":"Min, K. et al. Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy. J. Physiol. 593, 2017\u20132036 (2015).","journal-title":"J. Physiol."},{"key":"288_CR175","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1152\/japplphysiol.00429.2011","volume":"111","author":"AJ Smuder","year":"2011","unstructured":"Smuder, A. J., Kavazis, A. N., Min, K. & Powers, S. K. Exercise protects against doxorubicin-induced markers of autophagy signaling in skeletal muscle. J. Appl Physiol. 111, 1190\u20131198 (2011).","journal-title":"J. Appl Physiol."},{"key":"288_CR176","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1042\/bj2340653","volume":"234","author":"TC Laurent","year":"1986","unstructured":"Laurent, T. C., Fraser, J. R., Pertoft, H. & Smedsrod, B. Binding of hyaluronate and chondroitin sulphate to liver endothelial cells. Biochem. J. 234, 653\u2013658 (1986).","journal-title":"Biochem. J."},{"key":"288_CR177","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1074\/jbc.RA119.011571","volume":"295","author":"P Xia","year":"2020","unstructured":"Xia, P. et al. Doxorubicin induces cardiomyocyte apoptosis and atrophy through cyclin-dependent kinase 2-mediated activation of forkhead box O1. J. Biol. Chem. 295, 4265\u20134276 (2020).","journal-title":"J. Biol. Chem."},{"key":"288_CR178","doi-asserted-by":"publisher","unstructured":"Chan, B. Y. H. et al. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodeling. Cardiovasc. Res. https:\/\/doi.org\/10.1093\/cvr\/cvaa017 (2020).","DOI":"10.1093\/cvr\/cvaa017"},{"key":"288_CR179","doi-asserted-by":"publisher","first-page":"C613","DOI":"10.1152\/ajpcell.00113.2019","volume":"317","author":"X Ren","year":"2019","unstructured":"Ren, X., Lamb, G. D. & Murphy, R. M. Distribution and activation of matrix metalloproteinase-2 in skeletal muscle fibers. Am. J. Physiol. Cell Physiol. 317, C613\u2013C625 (2019).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"288_CR180","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.exger.2014.07.016","volume":"58","author":"S Sun","year":"2014","unstructured":"Sun, S. et al. Measurement of a MMP-2 degraded Titin fragment in serum reflects changes in muscle turnover induced by atrophy. Exp. Gerontol. 58, 83\u201389 (2014).","journal-title":"Exp. Gerontol."},{"key":"288_CR181","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10974-005-9020-y","volume":"26","author":"J Peng","year":"2005","unstructured":"Peng, J., Raddatz, K., Labeit, S., Granzier, H. & Gotthardt, M. Muscle atrophy in titin M-line deficient mice. J. Muscle Res. Cell Motil. 26, 381\u2013388 (2005).","journal-title":"J. Muscle Res. Cell Motil."},{"key":"288_CR182","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1161\/CIRCULATIONAHA.118.037588","volume":"139","author":"MH Radke","year":"2019","unstructured":"Radke, M. H. et al. Deleting full length titin versus the titin M-band region leads to differential mechanosignaling and cardiac phenotypes. Circulation 139, 1813\u20131827 (2019).","journal-title":"Circulation"},{"key":"288_CR183","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1073\/pnas.0608543104","volume":"104","author":"MH Radke","year":"2007","unstructured":"Radke, M. H. et al. Targeted deletion of titin N2B region leads to diastolic dysfunction and cardiac atrophy. Proc. Natl Acad. Sci. USA 104, 3444\u20133449 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"288_CR184","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/CIRCRESAHA.117.311335","volume":"122","author":"SK Gupta","year":"2018","unstructured":"Gupta, S. K. et al. Quaking inhibits doxorubicin-mediated cardiotoxicity through regulation of cardiac circular RNA expression. Circ. Res. 122, 246\u2013254 (2018).","journal-title":"Circ. Res."},{"key":"288_CR185","doi-asserted-by":"publisher","DOI":"10.1038\/srep32695","volume":"6","author":"TA Nissinen","year":"2016","unstructured":"Nissinen, T. A. et al. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci. Rep. 6, 32695 (2016).","journal-title":"Sci. Rep."},{"key":"288_CR186","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jcsm.12104","volume":"7","author":"EA de Lima Junior","year":"2016","unstructured":"de Lima Junior, E. A. et al. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J. Cachexia Sarcopenia Muscle 7, 615\u2013625 (2016).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR187","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1006\/exmp.2000.2353","volume":"70","author":"T Zima","year":"2001","unstructured":"Zima, T. et al. Acute doxorubicin (adriamycin) dosage does not reduce cardiac protein synthesis in vivo, but decreases diaminopeptidase I and proline endopeptidase activities. Exp. Mol. Pathol. 70, 154\u2013161 (2001).","journal-title":"Exp. Mol. Pathol."},{"key":"288_CR188","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm, K. N. & Tyler, D. J. The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity. Cardiovasc. Drugs Ther. 34, 255\u2013269 (2020).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"288_CR189","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/jat.3307","volume":"36","author":"LK Schnackenberg","year":"2016","unstructured":"Schnackenberg, L. K. et al. Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice. J. Appl. Toxicol. 36, 1486\u20131495 (2016).","journal-title":"J. Appl. Toxicol."},{"key":"288_CR190","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1096\/fj.201801862R","volume":"33","author":"R Ballaro","year":"2019","unstructured":"Ballaro, R. et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 33, 5482\u20135494 (2019).","journal-title":"FASEB J."},{"key":"288_CR191","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.hfc.2019.08.006","volume":"16","author":"M Valentova","year":"2020","unstructured":"Valentova, M., Anker, S. D. & von Haehling, S. Cardiac cachexia revisited: the role of wasting in heart failure. Heart Fail. Clin. 16, 61\u201369 (2020).","journal-title":"Heart Fail. Clin."},{"key":"288_CR192","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCRESAHA.116.310115","volume":"120","author":"H Taegtmeyer","year":"2017","unstructured":"Taegtmeyer, H., Karlstaedt, A., Rees, M. L. & Davogustto, G. Oncometabolic tracks in the heart. Circ. Res. 120, 267\u2013269 (2017).","journal-title":"Circ. Res."},{"key":"288_CR193","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","volume":"166","author":"MD Buck","year":"2016","unstructured":"Buck, M. D. et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell 166, 63\u201376 (2016).","journal-title":"Cell"},{"key":"288_CR194","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736\u2013746 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"288_CR195","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semcdb.2016.02.009","volume":"54","author":"TA Zimmers","year":"2016","unstructured":"Zimmers, T. A., Fishel, M. L. & Bonetto, A. STAT3 in the systemic inflammation of cancer cachexia. Semin. Cell Dev. Biol. 54, 28\u201341 (2016).","journal-title":"Semin. Cell Dev. Biol."},{"key":"288_CR196","doi-asserted-by":"publisher","first-page":"11177","DOI":"10.1074\/jbc.M115.641514","volume":"290","author":"KA Silva","year":"2015","unstructured":"Silva, K. A. et al. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. 290, 11177\u201311187 (2015).","journal-title":"J. Biol. Chem."},{"key":"288_CR197","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cmet.2013.07.012","volume":"18","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. Stat3 activation links a C\/EBPdelta to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 18, 368\u2013379 (2013).","journal-title":"Cell Metab."},{"key":"288_CR198","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/eurheartj\/ehq369","volume":"32","author":"A Haghikia","year":"2011","unstructured":"Haghikia, A. et al. Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur. Heart J. 32, 1287\u20131297 (2011).","journal-title":"Eur. Heart J."},{"key":"288_CR199","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3389\/fphar.2016.00436","volume":"7","author":"R Altara","year":"2016","unstructured":"Altara, R., Harmancey, R., Didion, S. P., Booz, G. W. & Zouein, F. A. Cardiac STAT3 deficiency impairs contractility and metabolic homeostasis in hypertension. Front. Pharmacol. 7, 436 (2016).","journal-title":"Front. Pharmacol."},{"key":"288_CR200","doi-asserted-by":"publisher","first-page":"118519","DOI":"10.1016\/j.bbamcr.2019.07.014","volume":"1867","author":"S Pietzsch","year":"2020","unstructured":"Pietzsch, S., Ricke-Hoch, M., Stapel, B. & Hilfiker-Kleiner, D. Modulation of cardiac AKT and STAT3 signalling in preclinical cancer models and their impact on the heart. Biochim. Biophys. Acta Mol. Cell Res. 1867, 118519 (2020).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"288_CR201","doi-asserted-by":"publisher","first-page":"58338","DOI":"10.18632\/oncotarget.16873","volume":"8","author":"X Cai","year":"2017","unstructured":"Cai, X. et al. Inflammatory factor TNF-alpha promotes the growth of breast cancer via the positive feedback loop of TNFR1\/NF-kappaB (and\/or p38)\/p-STAT3\/HBXIP\/TNFR1. Oncotarget 8, 58338\u201358352 (2017).","journal-title":"Oncotarget"},{"key":"288_CR202","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya, Y. et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. J. Clin. Invest. 124, 528\u2013542 (2014).","journal-title":"J. Clin. Invest."},{"key":"288_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05910-1","volume":"9","author":"JM Peterson","year":"2018","unstructured":"Peterson, J. M. et al. NF-kappaB inhibition rescues cardiac function by remodeling calcium genes in a Duchenne muscular dystrophy model. Nat. Commun. 9, 3431 (2018).","journal-title":"Nat. Commun."},{"key":"288_CR204","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1042\/BJ20100323","volume":"429","author":"A Cuadrado","year":"2010","unstructured":"Cuadrado, A. & Nebreda, A. R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 429, 403\u2013417 (2010).","journal-title":"Biochem. J."},{"key":"288_CR205","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tcb.2005.11.002","volume":"16","author":"F Lluis","year":"2006","unstructured":"Lluis, F., Perdiguero, E., Nebreda, A. R. & Munoz-Canoves, P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 16, 36\u201344 (2006).","journal-title":"Trends Cell Biol."},{"key":"288_CR206","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/jcsm.12354","volume":"9","author":"JL Brown","year":"2018","unstructured":"Brown, J. L. et al. Protein imbalance in the development of skeletal muscle wasting in tumour-bearing mice. J. Cachexia Sarcopenia Muscle 9, 987\u20131002 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"288_CR207","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1128\/MCB.20.11.3951-3964.2000","volume":"20","author":"Z Wu","year":"2000","unstructured":"Wu, Z. et al. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol. Cell Biol. 20, 3951\u20133964 (2000).","journal-title":"Mol. Cell Biol."},{"key":"288_CR208","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1101\/gad.1306705","volume":"19","author":"FB Engel","year":"2005","unstructured":"Engel, F. B. et al. p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes Dev. 19, 1175\u20131187 (2005).","journal-title":"Genes Dev."},{"key":"288_CR209","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fphar.2015.00102","volume":"6","author":"P Arabacilar","year":"2015","unstructured":"Arabacilar, P. & Marber, M. The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front. Pharmacol. 6, 102 (2015).","journal-title":"Front. Pharmacol."},{"key":"288_CR210","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/onc.2008.25","volume":"27","author":"DN Gross","year":"2008","unstructured":"Gross, D. N., van den Heuvel, A. P. & Birnbaum, M. J. The role of FoxO in the regulation of metabolism. Oncogene 27, 2320\u20132336 (2008).","journal-title":"Oncogene"},{"key":"288_CR211","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1042\/bj20030022","volume":"375","author":"T Furuyama","year":"2003","unstructured":"Furuyama, T., Kitayama, K., Yamashita, H. & Mori, N. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem. J. 375, 365\u2013371 (2003).","journal-title":"Biochem. J."},{"key":"288_CR212","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00018-013-1513-z","volume":"71","author":"AM Sanchez","year":"2014","unstructured":"Sanchez, A. M., Candau, R. B. & Bernardi, H. FoxO transcription factors: their roles in the maintenance of skeletal muscle homeostasis. Cell Mol. Life Sci. 71, 1657\u20131671 (2014).","journal-title":"Cell Mol. Life Sci."},{"key":"288_CR213","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","volume":"117","author":"M Sandri","year":"2004","unstructured":"Sandri, M. et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399\u2013412 (2004).","journal-title":"Cell"},{"key":"288_CR214","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1097-2765(04)00211-4","volume":"14","author":"TN Stitt","year":"2004","unstructured":"Stitt, T. N. et al. The IGF-1\/PI3K\/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14, 395\u2013403 (2004).","journal-title":"Mol. Cell"},{"key":"288_CR215","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1161\/CIRCULATIONAHA.106.637124","volume":"114","author":"YG Ni","year":"2006","unstructured":"Ni, Y. G. et al. Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation 114, 1159\u20131168 (2006).","journal-title":"Circulation"},{"key":"288_CR216","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-physiol-021909-135931","volume":"72","author":"SM Ronnebaum","year":"2010","unstructured":"Ronnebaum, S. M. & Patterson, C. The FoxO family in cardiac function and dysfunction. Annu. Rev. Physiol. 72, 81\u201394 (2010).","journal-title":"Annu. Rev. Physiol."},{"key":"288_CR217","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1172\/JCI31757","volume":"117","author":"HH Li","year":"2007","unstructured":"Li, H. H. et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J. Clin. Invest. 117, 3211\u20133223 (2007).","journal-title":"J. Clin. Invest."}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00288-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00288-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T08:34:17Z","timestamp":1670229257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-020-00288-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":217,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1038\/s41389-020-00288-6","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"22 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G. is co-founder and Board Member of Kither Biotech, a company focused on the development of PI3K inhibitors for airway diseases not in conflict with statements in this article. The other authors have no competing financial interest to disclose in relation to the work described. Work is supported by AIRC (P.E.P.: MFAG 21564; VR:23951), Ricerca Finalizzata (A.G.: RF-2013-02354892; V.S.: GR-2013-02355449), Fondazione Cariplo (V.S.: GR 2017-0800).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1"}}